About the 47th Symposium on Hormones and Cell Regulation
About the 47th Symposium on Hormones and Cell Regulation
G
protein-coupled receptors (GPCRs) are encoded by the most important
gene family in the human genome, representing 3% of the protein coding
genes (820 genes).
These cell surface receptors are expressed in every cell, and each cell
type express a large set of these receptors, varying during development
and physiological situations. Accordingly, GPCRs represent about 30% of
the targets of therapeutic drugs actually on the market, and still
represent a major interest in drug development programs.
Whereas GPCRs
were well recognized as targets for the treatment for various diseases
including allergy, psychiatric and neurologic, cardiovascular among
others, recent development revealed their high potential for the
treatment of various important diseases like cancers and metabolic
diseases.
The Mont Ste Odile meetings were established in the 50's by Jacques
Dumont with the idea to bring together scientists from both sides of the
last world war to strongly favor reconciliation.
This meeting concentrates on the mode of action of hormones and other
messengers in cell regulation, providing key information for drug
development.
The 47th meeting will be on Oct 1st-Oct 4th 2025, and dedicated to GPCRs
as novel targets for diseases. The meeting will bring three keynote
speakers, leaders in the field of GPCRs for the analysis of their
structure, and their interest in cancer and brain disease treatments.
It will be organized around 5 mini-symposia of 3-4 invited speakers and will cover novel topics in the field:
1) the analysis of GPCRs at the single molecule level, elucidating their
very precise location, and their structural dynamics, as important
aspects of their function and for the understanding of drug action
2) the recent observations that GPCRs offer novel possibilities to treat cancers
3) how GPCRs involved in the control of metabolism can be used to treat
various diseases
4) novel strategies to treat brain diseases, including
immunotherapies targeting GPCRs
5) the use of AI to better
characterize GPCR signaling properties and accelerate drug discovery.
Support will be provided to help young scientists to participate, and a
poster session will be organized to allow them to present their work.
In each session, three-four young scientists will be selected for a short presentation based on the abstracts submitted.
